Advertisement

Kylie Quinn

Dr Kylie Quinn is RMIT University Vice-Chancellor's Research Fellow and leads the new Ageing and Immunotherapies Group developing ways to improve immune responses in older individuals during infection, vaccination, and new cell-based therapies such as chimeric antigen receptor T cell therapy (CTT). Previously, she trained at the Vaccine Research Center (VRC), NIAID/NIH, USA, where she defined the mechanism of action for several novel vaccines and provided key pre-clinical data for Ebola vaccine selection by the World Health Organization in 2014.
Dr Kylie Quinn is RMIT University Vice-Chancellor's Research Fellow and leads the new Ageing and Immunotherapies Group developing ways to improve immune responses in older individuals during infection, vaccination, and new cell-based therapies such as chimeric antigen receptor T cell therapy (CTT). Previously, she trained at the Vaccine Research Center (VRC), NIAID/NIH, USA, where she defined the mechanism of action for several novel vaccines and provided key pre-clinical data for Ebola vaccine selection by the World Health Organization in 2014.
Languages Spoken:
English

Explainer | Covid-19: why a third shot is important for the immunocompromised

Some people with immunodeficiencies generate a lower immune response to Covid-19 vaccines, leading to increased breakthrough infections among them.

videocam
Related Topic
Coronavirus pandemic: All stories